ArticleBMC genomics2026
The genomic resource of Lysinibacillus fusiformis KBD-5, a biocontrol agent with antifungal activity against Botrytis cinerea.
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Lysinibacillus fusiformis strain KBD-5, previously known for its antiviral activity against Tobacco mosaic virus, was investigated for its biocontrol potential against the fungal pathogen Botrytis cinerea. In plate assays, conducted with three independent biological replicates and incubated at 28 °C for 5 days, KBD-5 significantly inhibited the mycelial growth of B. cinerea by 76.42%. Whole-genome sequencing revealed a 4.69 Mb genome with a GC content of 37.28%, encoding 4719 proteins. Bioinformatics analysis identified genes involved in antimicrobial functions, including 195 carbohydrate-active enzymes (potentially aiding in fungal cell wall degradation) and 8 gene clusters for secondary metabolite synthesis (e.g., T3PKS with 30% similarity to bacillibactin biosynthetic clusters and NRPS), indicating the production of antifungal metabolites like bacillibactin-like polyketides. The strain also showed a high safety profile with no significant virulence or drug resistance risks. These findings indicate that genomic analysis of KBD-5 reveals the potential for multiple biocontrol mechanisms, supporting its potential development as a biocontrol agent. The draft genome sequence is available under NCBI accession PRJNA1335659.
Indexed as
Identifiers
42332540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.